ÄϹ¬ng28ÏàÐÅÆ·ÅÆÁ¦Á¿

EN
ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾
Chronic Disease Drug Innovation Platform

Âý²¡Ò©´´ÐÂÆ½Ì¨

¾ß±¸ÁË´´ÐÂÒ©ÖØÐÂÑз¢£¬ÒÔ¼°¸ß¶Ë¿Ú·þ»º¿ØÊÍÔì¼ÁµÄÑз¢³ö²úÄÜÁ¦

¶à¸ö´´ÐÂÒ©Î﷢չȫÇòÁÙ´²ÊÔÑé

 


· ½¨ÓÐÂý²¡´´ÐÂÒ©¼¼ÊõÖÐÐÄ¡¢¿Ú·þ»º¿ØÊÍÔì¼Á×êÑг¢ÊÔÊҺͳö²ú¼¼Êõת»¯ÖÐÐÄ£¬¾ß±¸´´ÐÂÒ©È«Á÷³Ì¼°¶àÖÖ¼¼ÊõÀàÐ͸߶˿ڷþ»º¿ØÊÍÔì¼ÁµÄ×ÔÖ÷Ñз¢¼°³ö²úÄÜÁ¦ ¡£

 

· Óë¹ãÖݳ¢ÊÔÊÒ¹²½¨´´ÐÂÒ©¼¼Êõ²úҵת»¯ÖÐÐÄ£¬¼Ó¿ì´´ÐÂÒ©Ñз¢³ö²ú£¬Íƽø´´ÐÂÒ©²úÒµµÄ·¢Õ¹£¬ÊµÏÖ¿ÆÑÐÏîÄ¿³É¾Íת»¯ ¡£

 

  • ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾
    Ö÷ÌâÓÅÊÆ
      • ÒѳÉÁ¢Âý²¡´´ÐÂÒ©¼¼ÊõÖÐÐÄ¡¢¿Ú·þ»º¿ØÊÍÔì¼Á×êÑг¢ÊÔÊҺͳö²ú¼¼Êõת»¯ÖÐÐÄ

      • ¾ß±¸´´ÐÂÒ©È«Á÷³Ì¼°¶àÖÖ¼¼ÊõÀàÐ͸߶˿ڷþ»º¿ØÊÍÔì¼ÁµÄ×ÔÖ÷Ñз¢¼°³ö²úÄÜÁ¦

      • Óë¹ãÖݳ¢ÊÔÊÒ¹²½¨´´ÐÂÒ©¼¼Êõ²úҵת»¯ÖÐÐÄ£¬¼Ó¿ì´´ÐÂÒ©Ñз¢³ö²ú£¬Íƽø´´ÐÂÒ©²úÒµµÄ·¢Õ¹£¬ÊµÏÖ¿ÆÑÐÏîÄ¿³É¾Íת»¯

      rewrweer
  • ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾
    ²úÆ·¹ÜÏß
      • ÒÑÓÐ67¸öÂý²¡Ò©×¢²áÅú¼þ

      • º­¸ÇÐÄÄÔѪ¹Ü¼²²¡¡¢ÉöÔ༲²¡¡¢Ïû»¯ÏµÍ³¼²²¡¡¢¸Î²¡µÈ¼²²¡Ò½ÖÎÁìÓò

      rewrweer
  • ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾
    ÔÚÑйÜÏß
      • ÔÚÑÐÂý²¡Ò©Ô̺¬È«Çò´´ÐÂÒ©AR882µÈÏîÄ¿29¸ö

      • ¾ùÓµÓжÀ¼ÒרÀûºÍ¹ÖÒìÒ½ÖÎÓÅÊÆ

      • ÔÚÑÐÍ´·ç´´ÐÂÎïAR882³ÉЧÓÅÓÚÁÙ´²Ò»ÏßÒ©ÎӵÓÐÈ«Çò¾ºÕùÓÅÊÆ

      rewrweer
  • ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾
    ÓÅÁ¼³É¾Í
      • AR882ÒÑʵÏÖµÄÈ«Çò¶àÖÐÐÄ¢òBÆÚÁÙ´²ÊÔÑéÊý¾ÝÏÔʾ£ºAR882ÁÆÐ§¸üÏÔÖø£¬°²È«ÐÔ¸ü¸ß£¬ÓµÓгÉΪFirst-in-class ¼° Best-in-classÓÅÊÆ²úƷDZÁ¦£¬ÒÑ»ñµÃÃÀ¹úFDAÊÚÓèµÄ¼±¾çͨ·×ʸñ£¨FTD£©

      • ¶à¸ö²úÆ·ÈëÑ¡¡¶¹ú¶È¸ù»ùÒ©ÎïĿ¼¡·ºÍ¡¶¹ú¶ÈÒ½±£Ä¿Â¼¡·

      rewrweer

Âý²¡Ò©Ñз¢¹ÜÏß

ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾

ÄϹ¬NG¡¤28(ÖйúÇø)ÏàÐÅÆ·ÅÆÁ¦Á¿ÓÐÏÞ¹«Ë¾

¡¾ÍøÕ¾µØÍ¼¡¿